|
|
BioCryst Pharmaceuticals Inc.
|
 |
||||||||
|
 |
  |
 |
|
|
||
 |
 |
 
|
return to message board, top of board |
Shire expands Injectable HAE Market September 21, 2018 – Shire plc (LSE: SHP, NASDAQ: SHPG) the leading global biotechnology company focused on rare diseases, today announced that the Ministry of Health, Labour and Welfare (MHLW) in Japan has granted manufacturing and marketing authorisation for FIRAZYR® (icatibant injection), for the acute treatment of hereditary angioedema (HAE) attacks in adult patients with HAE. 7353/Zenith- answer the bell with an oral solution, and threaten to capture major market share- bring competitors to the table.....Q4 18..... Get it done Jon, Tom, Babu, BOD...... |
|
|
return to message board, top of board |
